Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

This publication has 20 references indexed in Scilit:

• Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT₃ receptor antagonist
  Alimentary Pharmacology & Therapeutics, 1999
• Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United Kingdom
  Digestion, 1999
• Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
  Alimentary Pharmacology & Therapeutics, 1998
• Impact of irritable bowel syndrome on quality of life
  Digestive Diseases and Sciences, 1996
• Variability of gastrointestinal transit in healthy women and men.
  Gut, 1996
• Modification of Visceral Sensitivity and Pain in Irritable Bowel Syndrome by 5-HT3 Antagonism (Ondansetron)
  Digestion, 1996
• Visceral perception in irritable bowel syndrome
  Digestive Diseases and Sciences, 1995
• Reduction of rectal sensitivity and post‐prandial motility by granisetron, a 5 HT₃‐receptor antagonist, in patients with irritable bowel syndrome
  Alimentary Pharmacology & Therapeutics, 1993
• Irritable bowel syndrome in the general population.
  BMJ, 1992
• Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5‐hydroxytryptamine receptor (type 3) antagonist
  Alimentary Pharmacology & Therapeutics, 1990